CREATE Medicines Acquires Monash's 8-Fold LNP Targeting Technology to Solve In Vivo CAR-T's Liver Delivery Problem
核心洞察
CREATE Medicines (搜索) secured worldwide exclusive rights to Monash University's TP1107 antibody-capture LNP system, which demonstrated an 8-fold increase in mRNA delivery to target cells in a 2025 Nature Nanotechnology study.
The deal arrives one day after CREATE received Australian ethics approval for its first-in-human Phase 1/2 trial of CRT-402 (搜索), an in vivo CAR-T candidate targeting CD19 (搜索) for autoimmune diseases (搜索).
The Monash technology orients antibodies on LNP surfaces via their Fc regions, ensuring optimal Fab exposure and enabling cell-type-specific delivery across T cells, NK cells, and myeloid cells.
Cambridge, Massachusetts-based CREATE Medicines (搜索) announced on July 31, 2026, a strategic research collaboration and exclusive license agreement with Australia's Monash University that directly targets the central unsolved engineering challenge in in vivo CAR-T therapy: getting lipid nanoparticles to deliver their mRNA payload to immune cells rather than defaulting to the liver. The deal grants CREATE worldwide exclusive rights to all intellectual property arising from the collaboration, including proprietary binder and chemistry technologies developed at the Monash Institute of Pharmaceutical Sciences (搜索) (MIPS).
The announcement came one day after CREATE received Human Research Ethics Committee approval in Australia to begin its first-in-human Phase 1/2 trial of CRT-402 (搜索), its lead in vivo CAR-T candidate for autoimmune diseases (搜索) — marking the company's fourth clinical program and its first outside oncology.
The Liver Default Problem
Standard lipid nanoparticles face a fundamental biological obstacle: after injection, apolipoprotein E adsorbs to LNP surfaces and redirects them to hepatocytes in the liver, regardless of the therapeutic target. For in vivo CAR-T therapies that need to reach T cells, NK cells, or myeloid cells circulating in blood and lymph nodes, this hepatic tropism represents a critical barrier.
The conventional workaround — conjugating antibodies to the LNP surface to redirect particles toward T-cell markers such as CD3, CD4, or CD7 (搜索) — suffers from a random orientation problem. Antibodies attached through standard conjugation methods end up with their antigen-binding Fab regions in inconsistent orientations: some face outward and remain available for target binding, while others are blocked by the LNP surface or obscured by PEG chains. This randomness reduces targeting efficiency and creates batch-to-batch variability.
The Monash Solution: TP1107 Capture System
The MIPS team, led by Professor Angus Johnston and including Professor Colin Pouton and Dr. Moore Chen, developed the TP1107 capture system — a method that attaches antibodies to the LNP surface specifically through their Fc regions, forcing the Fab binding arms outward in an optimal orientation. The result, published in Nature Nanotechnology in 2025, was an 8-fold increase in mRNA binding to target cells compared to conventional antibody capture methods.
Critically, the system is antibody-agnostic, meaning it can in principle be adapted to target any cell type for which a suitable surface marker and corresponding antibody exist. This versatility is precisely what attracted CREATE.
"Targeted delivery is one of the central challenges in realizing the promise of in vivo cell therapies and pairing our LNP technology with CREATE's platform is a powerful step toward solving it," Professor Johnston said in a statement.
Strategic Fit with CREATE's Multi-Lineage Ambitions
CREATE's existing mRNA-LNP platform has already demonstrated the ability to program immune cells inside human patients. The company has dosed more than 50 patients across its clinical programs to date — a figure it describes as the largest clinical dataset in the field of in vivo CAR therapy. Its four active programs target HER2 (搜索), TROP2 (搜索), and GPC3 (搜索) in solid tumors (搜索), and B cells expressing CD19 (搜索) in autoimmune disease.
The autoimmune program, CRT-402 (搜索), targets CD19 (搜索)-positive B cells abundant in blood and lymphoid tissue, aiming to drive autoimmune diseases (搜索) into remission. The in vivo approach eliminates the weeks-long ex vivo manufacturing process that conventional CAR-T requires, offering the potential for repeat dosing and off-the-shelf administration.
Solid tumors (搜索) present a harder challenge. At the American Association for Cancer Research meeting in 2026, CREATE presented data showing simultaneous engineering of myeloid cells, NK cells, and T cells with tailored CAR mRNAs, demonstrating tumor regression in a colorectal cancer (搜索) model. The company also introduced first-in-vivo data for RetroT, an all-RNA genome integration platform.
The Monash deal becomes strategically critical for this multi-lineage ambition. If the MIPS antibody-capture system can be validated for CD7 (搜索) (a T-cell marker), CD16 (搜索) (NK cells), or CD64 (搜索) (myeloid cells), CREATE gains a versatile toolkit for building next-generation LNP formulations that each hit a different immune cell type.
"Monash brings world-class LNP engineering and paired with our already clinically validated and targeted mRNA platform, we can further apply that precision across an even broader range of targets," said Daniel Getts, PhD, Founder and CEO of CREATE Medicines (搜索).
Robert Hofmeister, PhD, CREATE's Chief Scientific Officer, added that the partnership creates "a richer targeting toolkit with new binder formats and control that gives us even more ways to program the right cells with precision."
Competitive Landscape
The deal lands as the in vivo CAR-T field consolidates rapidly around large pharmaceutical acquirers. Eli Lilly acquired Orna Therapeutics (搜索) for up to $2.4 billion in February 2026, gaining a circular RNA platform using LNPs for delivery, and followed in April with a deal to acquire Kelonia Therapeutics (搜索) for up to $7 billion. Kelonia uses lentiviral vectors that stably integrate the CAR gene, producing permanent expression — its lead program showed a 100% overall response rate in 18 patients in Phase 1 data reported at ASCO 2026.
Johnson & Johnson announced on July 29, 2026, a collaboration with Sail Biomedicines (搜索) worth up to $925 million, including a $465 million equity stake and the right to acquire Sail outright for an additional $2.58 billion. AstraZeneca and AbbVie (搜索) have also entered the space through separate acquisitions.
CREATE distinguishes itself with the deepest clinical dataset among independent operators and, now, a proprietary targeting chemistry that competitors would need to develop or license independently.
H.C. Wainwright senior analyst Mitchel Kapoor noted that safety will be the key determinant for platform success — "convenience and efficacy won't be enough to impress investors" in a space where novel delivery mechanisms carry inherent unknown risk profiles. AstraZeneca's EsoBiotec saw "potentially concerning safety signals" in early Phase 1 data for multiple myeloma (搜索), underscoring the clinical hurdles ahead.
The Academic Partner
MIPS, the primary research hub of Monash University's Faculty of Pharmacy and Pharmaceutical Sciences, is ranked second globally in the QS World University Rankings by Subject. The institute employs more than 400 scientists focused on drug discovery, design, delivery, and use. Monash Vice-Chancellor Professor Sharon Pickering highlighted the university's commercial strategy, noting that Monash operates a commercial office in Boston — removing the friction that would typically accompany an Australian academic partnership with a Cambridge, Massachusetts-based biotech.
Under the agreement, MIPS will receive research funding and downstream milestone and royalty payments, while CREATE retains worldwide exclusive rights to all IP arising from the collaboration and the right to develop and commercialize CAR products directed to designated targets.
The Economic Case for In Vivo CAR-T
Conventional CAR-T therapy requires extracting a patient's T cells, shipping them to a manufacturing facility, genetically engineering them, expanding them, and reinfusing them — a process taking two to six weeks and costing approximately $400,000 or more per infusion. In vivo CAR-T collapses that manufacturing chain: mRNA-loaded LNPs can be manufactured at scale, stored, and shipped as a ready-made drug.
CREATE's mRNA approach offers an additional advantage: repeat dosing. Because mRNA-delivered CARs produce transient expression, patients can receive multiple infusions as needed. In autoimmune diseases (搜索) like lupus or systemic sclerosis, where immune dysregulation can recur, that capability is clinically meaningful — in vivo CAR-T can function more like a chronic therapy than a one-time intervention. The tradeoff — that mRNA cannot produce the same durable CAR expression as lentiviral integration — will be tested as CREATE and its competitors generate data across different disease indications.